- Cerus Corp. reported a record year with strong commercial growth and several pipeline wins. The company expects 2021 to be another record year.
- The FDA's decided to move the compliance date from April 1st, back to October 1st. Despite the setback, 2021 should be a transformative year for INTERCEPT.
- CERS has been under pressure following reports the NIH has terminated a convalescent plasma for COVID-19. I believe this sell-off is unjustified and is a buying opportunity.
For further details see:
Cerus Corp.: Remaining Bullish Despite Delayed Compliance Date